Log In
BCIQ
Print this Print this
 

CBT-102

  Manage Alerts
Collapse Summary General Information
Company CBT Pharmaceuticals Inc.
DescriptionInhibitor of the MAP kinase pathway
Molecular Target MAP kinase (MAPK) (ERK)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today